Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Revenue

Lineage Cell Therapeutics had revenue of $2.77M in the quarter ending June 30, 2025, with 96.38% growth. This brings the company's revenue in the last twelve months to $10.91M, up 76.43% year-over-year. In the year 2024, Lineage Cell Therapeutics had annual revenue of $9.50M with 6.19% growth.

• Revenue (ttm): $10.91M
• Revenue Growth: +76.43%
• P/S Ratio: 20.84
• Revenue / Employee: $141,740
• Employees: 77
• Market Cap: 232.92M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	9.50M	554.00K	6.19%
Dec 31, 2023	8.95M	-5.76M	-39.16%
Dec 31, 2022	14.70M	10.36M	238.70%
Dec 31, 2021	4.34M	2.52M	137.73%
Dec 31, 2020	1.83M	-1.69M	-48.05%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.